Menu
Search
|

Menu

Close
X

Fate Therapeutics Inc FATE.OQ (NASDAQ Stock Exchange Global Market)

16.14 USD
-1.62 (-9.12%)
As of Mar 22
chart
Previous Close 17.76
Open 17.61
Volume 295,189
3m Avg Volume 270,194
Today’s High 17.65
Today’s Low 16.13
52 Week High 19.11
52 Week Low 8.35
Shares Outstanding (mil) 65.00
Market Capitalization (mil) 1,049.09
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
5
FY17
4
FY16
4
EPS (USD)
FY18
-1.195
FY17
-1.021
FY16
-1.068
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.10
Price to Sales (TTM)
vs sector
221.33
8.84
Price to Book (MRQ)
vs sector
6.51
4.60
Price to Cash Flow (TTM)
vs sector
--
40.07
Total Debt to Equity (MRQ)
vs sector
9.28
17.66
LT Debt to Equity (MRQ)
vs sector
7.76
13.97
Return on Investment (TTM)
vs sector
-47.57
12.12
Return on Equity (TTM)
vs sector
-56.05
13.24

EXECUTIVE LEADERSHIP

William Rastetter
Independent Chairman of the Board, Since
Salary: --
Bonus: --
John Wolchko
President, Chief Executive Officer, Director, Since 2017
Salary: $480,000.00
Bonus: --
John Mendlein
Vice Chairman of the Board, Since 2017
Salary: --
Bonus: --
Sarah Cooley
Senior Vice President - Clinical Translation, Since 2019
Salary: --
Bonus: --
Daniel Shoemaker
Chief Scientific Officer, Since 2015
Salary: $352,500.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3535 General Atomics Ct Ste 200
SAN DIEGO   CA   92121-1140

Phone: +1858.8751803

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

SPONSORED STORIES